MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celyad SA Company Profile (NASDAQ:CYAD)

Consensus Ratings for Celyad SA (NASDAQ:CYAD) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $95.00 (122.27% upside)

Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016Piper JaffrayReiterated RatingOverweight$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Celyad SA (NASDAQ:CYAD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Celyad SA (NASDAQ:CYAD)
DateHeadline
06/23/16 02:04 AM3:04 am Celyad reports infusion of the first patient enrolled in the fourth dose level of its Phase I/IIa clinical trial -
06/23/16 12:09 AMCelyad treats first patient in the fourth dose level of its NKR-2 trial - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced the infusion of the first patient ...
06/14/16 08:20 AMCelyad : appoints Graham Morrell as Vice-President of Investors Relations & Communication
06/14/16 12:09 AMCelyad appoints Graham Morrell as Vice-President of Investors Relations & Communication - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
06/06/16 08:56 PMCelyad : appoints Dr. David Gilham as Vice-President of Research & Development
06/06/16 12:08 AMCelyad appoints Dr. David Gilham as Vice-President of Research & Development - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
06/01/16 10:04 AMCelyad: CAR Reaches The Highest Dose - Celyad SA (NASDAQ:CYAD) can now move to the highest planned dose of 3x107 cells in the important NKR-2 Phase II CAR trial. If the next 30m cell dose is also safe (and the MTD) it will lead to two separate six patient open label studies in Acute Myeloid ...
05/26/16 12:07 AMCelyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial - [at noodls] - The trial is a dose escalation study evaluating safety and feasibility of NKR-2 T-cell therapy in patients with Acute Myeloid Leukemia or Multiple Myeloma. No dose limiting toxicity reported in the last ...
05/24/16 02:00 PMNext Weeks Broker Price Targets For Celyad SA (CYAD) - Share Trading News - Next Weeks Broker Price Targets For Celyad SA (CYAD)Share Trading NewsCelyad SA has a 50 day moving average of 48.16 and a 200 day moving average of 44.60. The stock's market capitalization is 448.89M, it has a 52-week low of 32.00 and a 52-week high of 67.94. The share price of the company (CYAD) was down -3.60%, ...
05/24/16 02:00 PMEarnings Review and Stock Rundown for Celyad SA (ADR) (NASDAQ:CYAD) - Wall Street Hints and News - Earnings Review and Stock Rundown for Celyad SA (ADR) (NASDAQ:CYAD)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Celyad SA (ADR) (NASDAQ:CYAD) to post ...and more »
05/19/16 12:02 AMCelyad announces first quarter 2016 business update - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
05/11/16 01:48 PMConsensus Rating Review for Celyad SA (ADR) (NASDAQ:CYAD) - B.O.D.Y Confidential - Consensus Rating Review for Celyad SA (ADR) (NASDAQ:CYAD)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Celyad SA (ADR) (NASDAQ:CYAD). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/10/16 02:00 PMCelyad SA Ads (NASDAQ:CYAD) Sellers Increased By 66.18% Their Shorts - B.O.D.Y Confidential - Celyad SA Ads (NASDAQ:CYAD) Sellers Increased By 66.18% Their ShortsB.O.D.Y ConfidentialThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 66.18% in short interest. CYAD's total short interest was 45,200 shares in May as published by FINRA. Its up 66.18% from 27,200 shares, reported previously. With 4,400 shares average ...
05/04/16 01:24 PMAverage Analyst Rating for Celyad SA (ADR) (NASDAQ:CYAD) - B.O.D.Y Confidential - Average Analyst Rating for Celyad SA (ADR) (NASDAQ:CYAD)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Celyad SA (ADR) (NASDAQ:CYAD) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 12:10 AMCelyad Announces Oral Presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases ...
04/26/16 12:08 AMCelyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA) - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
04/23/16 01:37 PMCelyad SA (ADR) (NASDAQ:CYAD) Share Rating Recap - The Post - Celyad SA (ADR) (NASDAQ:CYAD) Share Rating RecapThe PostShares of Celyad SA (ADR) (NASDAQ:CYAD) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/19/16 08:45 AMCelyad SA :CYAD-US: Earnings Analysis: For the six months ended December 31, 2015 -
04/19/16 08:27 AMCelyad SA :CYAD-US: Earnings Analysis: 2015 By the Numbers -
04/16/16 01:09 PMCelyad SA (ADR) (NASDAQ:CYAD): Quick Look at Earnings - News Tribune - Celyad SA (ADR) (NASDAQ:CYAD): Quick Look at EarningsNews TribuneWhen Celyad SA (ADR) (NASDAQ:CYAD) issues their next quarterly report on or near N/A, Wall Street analysts are predicting they will report earnings per share of $N/A. This consensus EPS number is provided by Zacks Research, which might differ from ...and more »
04/16/16 01:09 PMCelyad SA (ADR) (NASDAQ:CYAD) Analyst Recommendation Outlook - Clinton Financial - Celyad SA (ADR) (NASDAQ:CYAD) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 2 analysts providing ratings for Celyad SA (ADR) (NASDAQ:CYAD). 3 have given the stock a “Strong Buy”, 0 rate it a “Buy”, ...Celyad SA Ads (NASDAQ:CYAD) Sellers Increased By 63.86% Their ShortsFranklin Independentall 2 news articles »
04/14/16 01:48 PMView on Ratings Celyad SA (ADR) (NASDAQ:CYAD) - Business Standard Tribune - View on Ratings Celyad SA (ADR) (NASDAQ:CYAD)Business Standard TribuneUsing a scale from 1 to 5, Celyad SA (ADR) (NASDAQ:CYAD) has a rating of 1 on the stock. A score of 1 or 2 indicates a Buy rating, and a score of 4 or 5 indicates a Sell rating. A 3 would indicate a Hold. This consensus number is made up of covering ...
04/14/16 12:05 AMCelyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting - [at noodls] - Mont-Saint-Guibert, Belgium- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies today announced its selection by the Scientific ...
04/13/16 12:59 PMCELYAD S.A. Financials -
04/12/16 01:40 PMCelyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased 67.68% After Market Selling - Business Standard Tribune - Celyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased 67.68% After Market SellingBusiness Standard TribuneThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 67.68% in short interest. CYAD's total short interest was 16,600 shares in April as published by FINRA. Its up 67.68% from 9,900 shares, reported previously. With 4,000 shares average ...
04/12/16 01:40 PMEarnings Watch on Celyad SA (ADR) (NASDAQ:CYAD) - RiversideGazette.com - Earnings Watch on Celyad SA (ADR) (NASDAQ:CYAD)RiversideGazette.comCelyad SA (ADR) (NASDAQ:CYAD) has a consensus earnings per share estimate for the current quarter of $N/A based on compiled analyst projections. The company is next expected to release earnings on or around N/A for the period ending N/A. For the ...and more »
04/08/16 01:44 PMCelyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased By 67.68% - Clinton Financial - Celyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased By 67.68%Clinton FinancialThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 67.68% in short interest. CYAD's total short interest was 16,600 shares in April as published by FINRA. Its up 67.68% from 9,900 shares, reported previously. With 4,000 shares average ...
04/08/16 01:44 PMLatest Analyst Ratings For Celyad SA (CYAD) - Share Trading News - Latest Analyst Ratings For Celyad SA (CYAD)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Celyad SA (CYAD). The most recent broker reports which have been released note that 3 analysts have a rating of “buy ...
04/08/16 01:44 PMIs Celyad SA (ADR) (NASDAQ:CYAD) a Consensus Buy? - Clinton Financial - Is Celyad SA (ADR) (NASDAQ:CYAD) a Consensus Buy?Clinton FinancialEquity research firms covering public U.S companies have a workforce of analysts dedicating their time covering the most popular stocks. Their reports are delivered to institutional investors in order to help make investment decisions. The information ...and more »
04/08/16 01:44 PMBroker Changes For Celyad SA (CYAD) - Risers & Fallers - Broker Changes For Celyad SA (CYAD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Celyad SA (CYAD). The latest broker reports which are currently outstanding on Friday 8th of April state 3 analysts have a rating of “strong buy”, 3 analysts “buy”, 0 ...
04/06/16 01:34 PMCelyad SA (CYAD) Latest Broker Views - Risers & Fallers - Celyad SA (CYAD) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Celyad SA (CYAD). According to the latest broker reports outstanding on Wednesday 6th of April, 3 analysts have a rating of “strong buy”, 3 analysts “buy”, 0 analysts ...
04/06/16 12:14 AMCelyad appoints leading international Immuno-Oncology experts to Scientific Advisory Board - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases ...
04/05/16 01:01 PMEarnings View for Celyad SA (ADR) (NASDAQ:CYAD) - RiversideGazette.com - Earnings View for Celyad SA (ADR) (NASDAQ:CYAD)RiversideGazette.comWall Street analysts have a current quarter EPS estimate of $N/A on shares of Celyad SA (ADR) (NASDAQ:CYAD). Analysts and investors will be looking ahead to the next company earnings report which is scheduled to be released on or around N/A for the ...and more »
04/03/16 12:53 PMAfter Last Week What Do Analysts Think Of Celyad SA (CYAD) - Share Trading News - After Last Week What Do Analysts Think Of Celyad SA (CYAD)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Celyad SA (CYAD). According to data from Reuters, 3 analysts have a rating of “buy”, 3 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform ...
04/02/16 01:20 PMCelyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 67.68% - Stock Caller - Celyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 67.68%Stock CallerThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 67.68% in short interest. CYAD's total short interest was 16,600 shares in April as published by FINRA. Its up 67.68% from 9,900 shares, reported previously. With 4,000 shares average ...
04/01/16 01:43 PMShould Investors Buy Celyad SA (ADR) (NASDAQ:CYAD)? - Clinton Financial - Should Investors Buy Celyad SA (ADR) (NASDAQ:CYAD)?Clinton FinancialOut of the 2 analysts covering shares of Celyad SA (ADR) (NASDAQ:CYAD), 3 rate it a “Strong Buy”, 0 rate it a “Buy”, 0 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale. Taking ...and more »
03/31/16 01:21 PMAverage Rating Watch Celyad SA (ADR) (NASDAQ:CYAD) - Business Standard Tribune - Average Rating Watch Celyad SA (ADR) (NASDAQ:CYAD)Business Standard TribuneStreet analysts that cover Celyad SA (ADR) (NASDAQ:CYAD) presently have an average broker rating of 1 on the stock. This average rating comes from Zacks Research compiling polled analyst ratings taken into consideration. The average rating falls on a ...and more »
03/30/16 01:07 PMNew Analyst Ratings On Celyad SA (CYAD) - Risers & Fallers - New Analyst Ratings On Celyad SA (CYAD)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Celyad SA (CYAD). The latest broker reports which are currently outstanding on Wednesday 30th of March state 3 analysts have a rating of “strong buy”, 3 analysts “buy”, ...
03/30/16 12:12 AMCelyad successfully completes safety follow-up of the first patient in the third dose level of its NKR-2 Trial - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases ...
03/29/16 01:18 PMCelyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 67.68% - RiversideGazette.com - Celyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 67.68%RiversideGazette.comThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 67.68% in short interest. CYAD's total short interest was 16,600 shares in March as published by FINRA. Its up 67.68% from 9,900 shares, reported previously. With 4,000 shares average ...Celyad SA (CYAD) Broker Price Targets For The Coming WeekShare Trading Newsall 2 news articles »
03/29/16 01:18 PMEarnings Outlook on Celyad SA (ADR) (NASDAQ:CYAD) - RiversideGazette.com - Earnings Outlook on Celyad SA (ADR) (NASDAQ:CYAD)RiversideGazette.comAnalysts and investors will be looking forward to the next earnings release from Celyad SA (ADR) (NASDAQ:CYAD) which is scheduled to be on or around N/A for the period ending N/A. Covering sell-side analysts have a current quarter earnings per share ...and more »
03/24/16 01:12 AMCelyad reports 2015 Financial and Operating results - [at noodls] - Key 2015 highlights: Completion of CHART-1 patient enrolment and treatment, confirming availability of Phase III data results by end of June 2016. CHART-2 IND approval by the FDA - trial initiation in ...
03/23/16 12:34 PMPrice Target Update On Celyad SA (CYAD) - Risers & Fallers - Price Target Update On Celyad SA (CYAD)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Celyad SA (CYAD). According to the latest broker reports 3 analysts have a rating of “buy”, 4 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform” and ...
03/23/16 12:34 PMAnalysis and Celyad SA (ADR) (CYAD) Earnings Review - OctaFinance.com - Analysis and Celyad SA (ADR) (CYAD) Earnings ReviewOctaFinance.comAnalysts await Celyad SA (ADR) (NASDAQ:CYAD) to reports earnings on March, 24. The stock decreased 2.39% or $1.17 on March 22, hitting $47.83. About 6,852 shares traded hands or 86.35% up from the average. Celyad SA (ADR) (NASDAQ:CYAD) has ...Celyad SA (NASDAQ:CYAD) To Release Earnings On ThursdayShare Trading Newsall 2 news articles »
03/22/16 12:59 PMLooking Ahead to Earnings for Celyad SA (ADR) (NASDAQ:CYAD) - RiversideGazette.com - Looking Ahead to Earnings for Celyad SA (ADR) (NASDAQ:CYAD)RiversideGazette.comInvestors and analysts will be looking ahead to Celyad SA (ADR) (NASDAQ:CYAD)'s next earnings report which is slated to be released sometime on or around 2016-03-24 for the period ending on 2015-12-31. Street analysts have a consensus EPS ...Celyad SA (CYAD) New Analyst RatingsShare Trading Newsall 2 news articles »
03/22/16 01:10 AMCelyad announces collaboration with Institut Curie for the development of its immuno-oncology program NKR-T - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
03/20/16 12:42 PMCelyad SA (CYAD): Analyst Targets For The Coming Week - Share Trading News - Celyad SA (CYAD): Analyst Targets For The Coming WeekShare Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Celyad SA (CYAD). According to data from Reuters, 3 analysts have a rating of “buy”, 4 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform ...
03/16/16 01:05 PMCelyad SA (CYAD) Updated Price Targets - Share Trading News - Celyad SA (CYAD) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Celyad SA (CYAD). The most recent broker reports which have been released note that 3 analysts have a rating of “buy ...
03/09/16 12:23 PMStocks With High Analyst Interest: AMAG Pharmaceuticals, Inc ... - RiversideGazette.com - Stocks With High Analyst Interest: AMAG Pharmaceuticals, Inc ...RiversideGazette.comWall Street analysts are maintaining Buy rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) company shares. The one year target on the name currently ...and more »
01/05/16 12:06 AMCelyad completes 30-day safety follow-up of first patient of second cohort in NKG2D CAR T-Cell Phase I Trial - [at noodls] - No dose limiting toxicity related to the investigational treatment reported at 30 days post treatment of the first patient of the second dose-level; The trial is a dose escalation study evaluating safety ...
About Celyad SA

Celyad SA logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYAD
  • CUSIP:
Key Metrics:
  • Previous Close: $42.74
  • 50 Day Moving Average: $49.79
  • 200 Day Moving Average: $45.38
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $398.04M
  • Current Quarter EPS Consensus Estimate: $-5.02 EPS
Additional Links:
Celyad SA (NASDAQ:CYAD) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha